| Document |
Document Title |
|
WO/2024/040227A2 |
The embodiments disclosed herein provide methods and compounds directed to easily accessible and relatively abundant sources of human β- or y-actin (i.e., cytoplasmic actins). According to embodiments disclosed herein, Saccharomyces cer...
|
|
WO/2024/040245A1 |
The present disclosure relates to peptide having a sequence comprising: X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23
X24X25X26X27X28NH2 (SEQ ID NO: 1), And to their isomers, pharmaceutically acceptable salts, or prodrugs ...
|
|
WO/2024/038112A1 |
Via yeast display technology, albumin binding variants were selected, and variants displayed improved binding to MSA or both HSA & MSA. All variants were subcloned into the pHEN-expression plasmid and expressed in E coli WK6 cells. Purif...
|
|
WO/2024/040032A1 |
The present disclosure relates generally to the manipulation of chimeric polypeptide signaling to decrease cancer cell proliferation, and particularly to a new class of receptors engineered to (i) bind a target cell-surface displayed lig...
|
|
WO/2024/037005A1 |
The present invention provides a human cytomegalovirus antigen epitope chimeric peptide and a use thereof. An amino acid sequence of the human cytomegalovirus antigen epitope chimeric peptide is selected from SEQ ID NO.1, SEQ ID NO.2, SE...
|
|
WO/2024/039631A1 |
Embodiments of the present disclosure pertain to a composition that is suitable for use in treating or preventing arterial stiffness in a subject. In some embodiments, the composition includes a recombinant human thioredoxin (rhTrx), der...
|
|
WO/2024/038183A1 |
The present invention relates to multi-domain, single-chain binding molecules. The molecules comprise i) a peptide-major histocompatibility complex (pMHC) binding domain comprising a first variable region linked to a constant region (VC1...
|
|
WO/2023/101603A9 |
The invention concerns a novel therapeutic comprising a secretome obtained from mesenchymal stem cells of umbilical cord tissue or of wharton's jelly tissue and a formulation or pharmaceutical composition including same; ideally, but not...
|
|
WO/2024/035137A1 |
The present invention relates to a Bacillus subtilis flagellin variant and a use thereof, and more specifically to a flagellin variant and a use thereof, the flagellin variant having improved storage stability and reduced immunogenicity ...
|
|
WO/2024/032081A1 |
The present invention provides a preparation method for semaglutide, and an intermediate. The preparation method comprises the steps of: (1) reacting compound SEM110 and compound SEM120 in a solvent under an alkaline condition to obtain ...
|
|
WO/2024/036250A2 |
Provided herein are adeno-associated virus (AAV) compositions that can express an arylsulfatase A (ARSA) polypeptide in a cell, thereby restoring the ARSA gene function. Also provided are methods of using the AAV compositions, and packag...
|
|
WO/2024/032467A1 |
Disclosed in the present invention are a high-stability recombinant collagen, and a construction method therefor and the use thereof. On the basis of an original collagen sequence, one or more mutations selected from a group consisting o...
|
|
WO/2024/032398A1 |
The present invention relates to the technical field of genetic engineering and bioinformatics, and particularly, to a method for specifically improving lactoferrin (LTF) gene expression and use thereof. The method promotes LTF gene expr...
|
|
WO/2024/033903A1 |
The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bact...
|
|
WO/2024/033329A2 |
The present disclosure relates to antagonists that target, directly or indirectly, Serine/Arginine Rich Splicing Factor 1 (SRSF1); viral vectors comprising a nucleic acid sequence encoding SRSF1 antagonists. The use of said vector in gen...
|
|
WO/2024/035023A1 |
The present invention provides: a Bax protein variant in which lysine at position 128, lysine at position 190, or lysines at positions 128 and 190 in a Bax protein is(are) substituted with arginine; a method for increasing the half-life ...
|
|
WO/2024/033447A1 |
Aspects of the disclosure relate to protein pore complexes and their uses in analyte detection and characterisation. The disclosure is based, in part, on nanopore complexes formed by CsgG-like pores and one or more auxiliary proteins, wh...
|
|
WO/2024/036135A2 |
The invention is directed to immunogenic compositions and method of treatment comprising a peptide or nucleic acid that encodes the peptide that induces an immune response in a mammal that is protective against infection by one or more p...
|
|
WO/2024/033652A1 |
The invention provides, in some aspects, peptides, kits comprising the same and methods of using such peptides for diagnosing/treating type 1 diabetes (T1D) and latent autoimmune diabetes in adults (LADA) and methods of determining the t...
|
|
WO/2024/036234A1 |
Disclosed herein are systems and methods for screening variant libraries for activity. Also disclosed herein are high throughput methods for identifying candidate variant having gain of function biological activity in an assay. The discl...
|
|
WO/2024/036178A2 |
Provided is an adapter comprising an antibody binding domain (AbBD) that specifically binds and crosslinks to an immunoglobulin Fab region, where the AbBD is a variant of a Protein A domain D and has an amino acid replacement/modificatio...
|
|
WO/2024/031131A1 |
The present disclosure relates generally to novel compositions and methods for delivery of truncated midkine proteins in which the amino acid sequence encoded by exon 4 of human midkine is absent or partially absent and/or polynucleotide...
|
|
WO/2024/034622A1 |
The purpose of the present invention is to provide a means for selecting a subject-derived neoantigen. The above problem is solved by providing, for example, a method for selecting a subject-derived neoantigen, said method comprising: ...
|
|
WO/2024/032713A1 |
Provided are compositions comprising the HKUOT-S2 protein, at least one peptide according to at least one of SEQ ID NO: 81-97, or proteins comprising an amino acid sequence according to at least one of SEQ ID NO: 81-97. Provided are meth...
|
|
WO/2024/032020A1 |
The present invention relates to the field of recombinant protein technology, and particularly, to an enhanced monomeric StayGold protein and use thereof. The sequence of the enhanced monomeric StayGold protein is a mutant sequence of th...
|
|
WO/2024/036257A1 |
Provided herein are methods for treating drug addiction in a subject, the method comprising activating neurokinin B (NKB)-expressing neurons of the subject. Also provided herein are compositions useful for the treatment of drug addiction...
|
|
WO/2024/031921A1 |
Disclosed in the present invention are Pichia pastoris with enhanced lactoferrin expression, a method for constructing same, and use thereof. According to the present invention, commonly used signaling peptides are first screened, and th...
|
|
WO/2024/036217A2 |
Immunization strategies to naturally guide the maturation of antibodies against the human immunodeficiency virus (HIV) in HIV-infected subjects are described. The strategies include immunization utilizing an HIV envelope protein (Env) th...
|
|
WO/2024/036148A1 |
The disclosure relates to immune cells for treatment of blood cancer comprising an activator receptor comprising an extracellular ligand binding domain specific to an activator antigen expressed by blood cancer cells and an inhibitor rec...
|
|
WO/2024/035782A1 |
The invention described herein provides an engineered insulin polypeptide comprising two cleavable peptides interposed between the insulin B-chain and the C-peptide, and between the C-peptide and the insulin A-chain to secrete active ins...
|
|
WO/2024/033642A1 |
The present invention relates to optimising the effector function of an immune effector cell that expresses a chimeric antigen receptor (CAR) the co-localises with an accessory receptor, by ensuring that the intermembrane distance spanne...
|
|
WO/2024/033901A1 |
Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expre...
|
|
WO/2024/033400A1 |
Pancreatic Ductal Adenocarcinoma (PDAC) still represents a therapeutic dead-end. The inventors report that the K+ channel SK2 is stimulated by secreted cues from cancer-associated- fibroblasts (CAF) leading to the activation of an Integr...
|
|
WO/2024/032457A1 |
Disclosed in the present invention is a long-acting teriparatide compound. The long-acting compound of the present invention is used for preparing a pharmaceutical composition for treating diseases, and the pharmaceutical composition is ...
|
|
WO/2024/035721A1 |
Observing DNA-binding proteins interact with DNA substrates in real-time at the single-molecule level illuminates how proteins detect and bind to their targets at extraordinary detail. Accordingly, there is a need in the art for new tech...
|
|
WO/2024/032485A1 |
The present invention relates to a non-phosphorylated and non-ubiquitinated CREPT protein and use thereof. Specifically, the present invention relates to a protein that is obtained by modifying CREPT or a homologous protein thereof. The ...
|
|
WO/2024/033422A1 |
The present invention relates to novel pore monomer conjugates, pore complexes formed from the conjugates and their uses in analyte detection and characterisation.
|
|
WO/2024/035526A1 |
Disclosed are engineered nanobodies against different target antigens such as the spike protein of the SARS-CoV-2 virus and or to the ACE2 receptor at the host cell surface, binds to the virus or the ACE2 receptor at the host cell plasma...
|
|
WO/2024/036106A1 |
A non-human animal comprising chimeric microglia and methods of performing blastocyst microglia complementation to produce such a non-human chimeric animal are disclosed. In particular, the disclosed methods can be used to produce a non-...
|
|
WO/2024/031181A1 |
Breast cancer is now the most prevalent cancer worldwide, and despite therapeutical advances in the last decades, metastatic breast cancer remains an incurable disease. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (...
|
|
WO/2024/032821A1 |
Provided is a new and highly toxic amyloid oligomer Aβo*3F. The Aβo*3F is specifically bound by a 3F antibody, is the most important toxic ingredient in a mixture of Aβ oligomers, and has a strong pathogenic effect. Further provided i...
|
|
WO/2024/033443A1 |
The present invention relates to novel pore monomer conjugates, pore complexes formed from the conjugates and their uses in analyte detection and characterisation.
|
|
WO/2024/032454A1 |
Disclosed in the present invention is a long-acting abaloparatide compound. The long-acting compound of the present invention is used for preparing a pharmaceutical composition for treating diseases. Provided is a use of the pharmaceutic...
|
|
WO/2024/036005A1 |
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
|
|
WO/2024/033794A1 |
The present disclosure relates to a composition comprising one or more ribonucleic acids (RNAs) encoding virus-like particle (VLP) forming elements of an influenza virus. The present disclosure further provides uses of the composition.
|
|
WO/2024/036240A1 |
This invention relates to compositions and methods for modifying COMPACT PLANT2 (CT2) genes in plants, optionally to modify meristem size. The invention further relates to plants having improved yield traits produced using the methods an...
|
|
WO/2024/036303A2 |
The invention provides a modified HLA-E single chain trimer construct and nucleic acid molecules encoding thereof as well as cells and compositions comprising thereof for increasing the persistence or reducing the clearance of at least o...
|
|
WO/2024/034631A1 |
The present invention is a modified fibroin that contains a domain sequence represented by formula 1: [(A)n motif-REP]m or formula 2: [(A)n motif-REP]m-(A)n motif and has a GQ motif content of 12.5% or less. (In formulae 1 and 2, (A)n mo...
|
|
WO/2024/033879A1 |
The present disclosure relates to modified cells, e.g., chimeric antigen receptor (CAR) T cells and/or exogenous T cell receptor (eTCR) cells, which have reduced in vivo immunogenicity, and the use thereof.
|
|
WO/2024/032681A1 |
Provided are a method for adjusting the expression level of a target gene and a nucleic acid binding molecule. The combination of the nucleic acid binding molecule and a gene expression regulation molecule has the ability of adjusting th...
|
